Zentalis Pharmaceuticals, Inc.
NASDAQ:ZNTL
Overview | Financials
Company Name | Zentalis Pharmaceuticals, Inc. |
Symbol | ZNTL |
Currency | USD |
Price | 2.99 |
Market Cap | 213,083,546 |
Dividend Yield | 0% |
52-week-range | 2.66 - 18.07 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Kimberly Lynn Blackwell M.D. |
Website | https://zentalis.com |
An error occurred while fetching data.
About Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors;
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD